SCHEDULE: Lynx1 Capital Discloses 9.8% Stake in Cullinan Therapeutics
Beneficial Ownership Report (Amendment)
Lynx1 Capital Management LP and Weston Nichols reported a 9.8% beneficial ownership stake in Cullinan Therapeutics, Inc. as of September 30, 2025.
Summary
- Lynx1 Capital Management LP and Weston Nichols collectively reported beneficial ownership of 5,766,090 shares of Cullinan Therapeutics, Inc. common stock.
- This represents a 9.8% stake in the company's common stock.
- The ownership percentage is calculated based on 59,074,391 shares outstanding as of July 31, 2025, as reported in Cullinan Therapeutics' Quarterly Report on Form 10-Q for the period ended June 30, 2025.
- This filing is an Amendment No. 2 to a Schedule 13G, reflecting beneficial ownership as of September 30, 2025.
- The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply indicates a significant stake by an institutional investor.
Risks
- The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11. This statement mitigates immediate concerns about activist investor intervention.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.8% stake by an institutional investor like Lynx1 Capital Management LP could be viewed positively by other shareholders, signaling confidence in Cullinan Therapeutics.
- Management: The presence of a large institutional holder may lead to increased scrutiny or engagement from the investor, though the filing states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-07-31 | Date as of which 59,074,391 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-08-07 | Date Cullinan Therapeutics' Quarterly Report on Form 10-Q for Q2 2025 was filed, reporting shares outstanding. |
| 2025-09-30 | Date of event which requires filing of this statement, reflecting the beneficial ownership. |
| 2025-10-10 | Date of beneficial ownership reflected in Amendment No. 1 filing. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 2 was signed by the reporting persons. |
Keywords
Cullinan Therapeutics, Lynx1 Capital Management, Weston Nichols, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.